We initially sought to demonstrate the performance of scPred by making computational predictions of tumor and non-tumor cells based on their transcriptomes and validating our classification using a cell-specific independent immunohistochemistry assay targeting the MLH1 and PMS2 protein expression. This evidence concerns the gene PMS2 and neoplasm.